Oculis Holding AG
NASDAQ:OCS
Oculis Holding AG
Research & Development
Oculis Holding AG
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Oculis Holding AG
NASDAQ:OCS
|
Research & Development
-CHf11.7m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Novartis AG
SIX:NOVN
|
Research & Development
-$10.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-2%
|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Research & Development
-$422.1k
|
CAGR 3-Years
59%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Roche Holding AG
SIX:ROG
|
Research & Development
-CHf12.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-4%
|
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Research & Development
-$1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
Oculis Holding AG
Glance View
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improve eye care. The company is headquartered in Zug, Zug and currently employs 28 full-time employees. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
See Also
What is Oculis Holding AG's Research & Development?
Research & Development
-11.7m
CHF
Based on the financial report for Dec 31, 2024, Oculis Holding AG's Research & Development amounts to -11.7m CHF.
What is Oculis Holding AG's Research & Development growth rate?
Research & Development CAGR 3Y
-38%
Over the last year, the Research & Development growth was -73%. The average annual Research & Development growth rates for Oculis Holding AG have been -38% over the past three years .
